Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Tenofovir to Abacavir for Bone Mineral Density in HIV
NCT01153217Phase 3Completed
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Jul 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abacavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoints: Bone Mineral Density at 48 weeks and T-score change at 48 weeks. Started Jul 2010; status: completed.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01153217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153217.